175204-38-3 Usage
General Description
[3-(2,6-DICHLOROPHENYL)-5-METHYLISOXAZOL-4-YL]METHANOL is a chemical compound that contains a 3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl group attached to a methanol molecule. The 3-(2,6-dichlorophenyl) group consists of a benzene ring with two chlorine atoms attached to it, and the 5-methylisoxazol-4-yl group is a five-membered heterocyclic ring containing both nitrogen and oxygen atoms. When combined with the methanol molecule, this compound may have applications in pharmaceuticals, agrochemicals, or other industries due to its potentially unique physical and chemical properties. Further research and testing would be required to fully understand the uses and effects of this compound.
Check Digit Verification of cas no
The CAS Registry Mumber 175204-38-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,5,2,0 and 4 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 175204-38:
(8*1)+(7*7)+(6*5)+(5*2)+(4*0)+(3*4)+(2*3)+(1*8)=123
123 % 10 = 3
So 175204-38-3 is a valid CAS Registry Number.
InChI:InChI=1/C11H9Cl2NO2/c1-6-7(5-15)11(14-16-6)10-8(12)3-2-4-9(10)13/h2-4,15H,5H2,1H3
175204-38-3Relevant articles and documents
COMPOUNDS FOR MODULATING FXR
-
Paragraph 000140; 000154; 000155; 000519; 000523; 000524, (2020/12/30)
Provided herein are compounds of Formula (I), a stereoisomer, enantiomer or a pharmaceutically acceptable salt thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
3,4,5-Trisubstituted isoxazoles as novel PPARδ agonists: Part 1
Epple, Robert,Russo, Ross,Azimioara, Mihai,Cow, Christopher,Xie, Yongping,Wang, Xing,Wityak, John,Karanewsky, Don,Gerken, Andrea,Iskandar, Maya,Saez, Enrique,Martin Seidel,Tian, Shin-Shay
, p. 4376 - 4380 (2007/10/03)
We report the identification of a novel series of trisubstituted isoxazoles as PPAR activators from a high-throughput screen. A series of structural optimizations led to improved efficacy and excellent functional receptor selectivity for PPARδ. The isoxazoles represent a series of agonists which display a scaffold that lies outside the typical PPAR agonist motif.